Mandate

Vinge advises Main Capital and Aunetic in connection with the acquisition of Qnister

Vinge has advised Aunetic, a leading governance software specialist, in connection with the acquisition of Qnister AB (“Qnister”). The strategic acquisition enhances Aunetic’s product portfolio and strengthens its presence in the Swedish software compliance market.

Founded in 2017, Qnister is as a SaaS-company specialising in compliance software solutions, providing GDPR and whistleblowing solutions as well as services in sanctions screening and contract management to small and medium-sized enterprises in the private sector and to customers within the public sector.

The acquisition aligns with Aunetic’s goal to expand its compliance software suite and market reach, positioning Aunetic as a leading governance software group in Europe.

Vinge’s team mainly consisted of Filip Öhrner, Linus Adolfsson, Jonatan Stentorp (M&A), Emil Lindwall, Gulestan Ali (Employment), Carla Håkansson (Commercial Agreements & GDPR), Ian Jonson (IP) and Gabriella Balbo (Transaction Support Coordinator).

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025